Details of the Drug

General Information of Drug (ID: DMDZBTY)

Drug Name
HuM195/rGel
Synonyms
HuM195/rGel, MD Anderson; Conjugated anti-CD33 antibodies (cancer), MD Anderson; HuM195-gelonin immunotoxin (leukemia), Targa Therapeutics; HuM195/rGel (leukemia), Targa Therapeutics; Anti-CD33 immunotoxin (leukemia), Memorial Sloan-Kettering; HuM195-gelonin immunotoxin, Memorial Sloan-Kettering/MD Anderson; HuM195/rGel (intravenous infusion, AML/CML/meylodisplastic syndrome); HuM195/rGel (intravenous infusion, AML/CML/meylodisplastic syndrome), Targa Therapeutics; HuM195/rGel (intravenous infusion, acute myelogenous leukemia/chronic myelogenous leukemia/meylodisplastic syndrome), Targa Therapeutics
Indication
Disease Entry ICD 11 Status REF
leukaemia 2A60-2B33 Phase 1 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D06JQS

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Myeloid cell surface antigen CD33 (CD33) TTJVYO3 CD33_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease leukaemia
ICD Disease Classification 2A60-2B33
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Myeloid cell surface antigen CD33 (CD33) DTT CD33 5.37E-13 0.58 1.13
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007636)
2 Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica. 2013 Feb;98(2):217-21.